Open AccessEntecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching
Author(s) -
Tao Li,
Yundong Qu,
Yan Wang,
Cui-Wu Lin,
Baohua Yang,
Lei Wang
Publication year - 2019
Publication title -
jcpsp
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 33
eISSN - 1681-7168
pISSN - 1022-386X
DOI - 10.29271/jcpsp.2019.04.317
Subject(s) - entecavir , propensity score matching , medicine , hepatocellular carcinoma , gastroenterology , hepatology , cirrhosis , incidence (geometry) , proportional hazards model , cohort , hepatitis b virus , virology , virus , lamivudine , physics , optics
To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients.